MoonLake Immunotherapeutics
NASDAQ:MLTXBiotechnology
+$0.13 today
- Market cap
- $918.30M
- Beta
- 1.04
- P/E (TTM)
- -5.4
- EPS (TTM)
- -$3.61
Volume 1.32M
Average 0.99M
MLTX Net Income
Bottom-line profit, the starting point for calculating cash from operations.
MoonLake ImmunotherapeuticsNASDAQ: MLTX
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income grows, but more slowly than its trailing trend
Q1 FY2026 net income of $69.71M (cash outflow) rose 71.9% year over year, behind the +76.5% change in trailing-twelve-month net income. Sequentially, it rose 10.6% from the prior quarter. Over 3 fiscal years it compounded at +66.1% a year.
Context
- Net income grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate of -$246.47M (+7.6%) for the fiscal year ending Dec 2026, a slowdown from the +89.0% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$69.71M+10.6% QoQ
- Last fiscal yearDec 2025
- -$229.1M+89.0% YoY
- LTMMar 2026
- -$259.47M+76.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +71.9% | +18.4% | -53.5 pp |
| 1 year | +89.0% | +7.6% | -81.4 pp |
| 3-year CAGR | +66.1% | +5.3% | -60.8 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (229.1M) USD
- Year-over-year change
- -89.0%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (229.1M) | -89.0% |
| FY2024 | 2024-12-31 | (121.24M) | -175.1% |
| FY2023 | 2023-12-31 | (44.08M) | +11.8% |
| FY2022 | 2022-12-31 | (49.97M) | +6.8% |
| FY2021 | 2021-12-31 | (53.64M) | — |
Net Income vs competitors
How MLTX compares with its peers on the latest reported figures
- MLTX's LTM Mar 2026 net income of $259.47M is the 3rd largest of the 11 companies compared; the peer median is $65.28M.
- Its year-over-year change of +76.5% is the 4th highest of 11, against a peer median of +43.2%.
- Over three fiscal years its annual growth of +66.1% compares with a peer median of +21.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $438.96M | +92.9% | +29.5% | 5933.5% |
| LTM Aug 2026 | $294.88M | +220.5% | +13.6% | 42.0% | |
| LTM Mar 2026 | $259.47M | +76.5% | +66.1% | — | |
| LTM Jun 2026 | $192.25M | +67.5% | +78.6% | 10097.0% | |
ORKAOruka Therapeutics, Inc. | LTM Sep 2026 | $152.57M | +50.1% | +119.8% | — |
ZURAZura Bio Limited | LTM Mar 2026 | $77.43M | +24.7% | +35.9% | — |
| LTM Mar 2026 | $69.66M | -46.5% | -9.3% | 832.6% | |
| FY2025 | $60.9M | +35.2% | — | 4511.0% | |
| FY2025 | $55.48M | +255.0% | -21.8% | 86687.5% | |
| LTM Mar 2026 | $26.79M | -81.0% | — | 11.5% | |
| LTM Mar 2026 | $19.06M | +36.2% | -28.9% | — | |
| Peer median (excluding MLTX) | $65.28M | +43.2% | +21.6% | 4511.0% | |
Competitors are the stored peer set for MLTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (53.64M) | (49.97M) | (44.08M) | (121.24M) | (229.1M) |
| Depreciation & Amortization | 4.97K | 12.36K | 13.16K | 1.38M | 2.62M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 10.86M | 9.65M | 7.11M | 7.28M | 12.9M |
| Change in Working Capital | 4.48M | (1.43M) | (6.22M) | (3.78M) | 19.88M |
| Accounts Receivables | (148.77K) | (68.36K) | (840K) | (1.79M) | (2.03M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.57M | (1.31M) | 0 | 0 | 0 |
| Other Working Capital | 3.06M | (44.8K) | (6.22M) | (2M) | 21.9M |
| Other Non-Cash Items | 13.98M | (4.51M) | 399.51K | (225.71K) | (2.3M) |
| Operating Cash Flow | (35.18M) | (55.89M) | (42.78M) | (116.59M) | (196.01M) |
| Capital Expenditures | (50.71K) | (16.01K) | (284.63K) | (519.52K) | (35K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (42.23M) | (175.73M) | (350.28M) | (265.37M) |
| Sales of Investments | 0 | 9.9M | 150.83M | 145.2M | 468.4M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (50.71K) | (32.34M) | (25.18M) | (205.6M) | 202.99M |
| Debt Repayment | 15M | (15M) | 0 | 0 | 73.02M |
| Common Stock Issued | 28.27M | 3.79K | 482.45M | 52.54M | 72.98M |
| Common Stock Repurchased | (6.2K) | 0 | 0 | (50) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 134.69M | (2.75M) | (1.23M) | 0 |
| Financing Cash Flow | 43.26M | 119.69M | 479.7M | 51.31M | 146M |
| Effect of Forex Changes | (1.33M) | 8.54K | (75.31K) | 127.97K | 1.11M |
| Net Change in Cash | 6.7M | 31.47M | 411.66M | (270.74M) | 154.09M |
| Free Cash Flow | (35.23M) | (55.91M) | (43.06M) | (117.11M) | (196.04M) |
MoonLake Immunotherapeutics
NASDAQ:MLTX
Intrinsic Alpha fair value
Locked
Current Price
$10.79
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.